Evidence map›Paper›PMID 31559955›Full record

ArticleThe Lancet. Infectious diseases2019

Vaccine against Middle East respiratory syndrome coronavirus.

Alimuddin Zumla, Ziad A Memish, David S Hui, Stanley Perlman

Abstract readLetterComment
In one paragraph

Article in The Lancet. Infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2020
    Article
  4. Article
  5. Article
  6. Article
  7. Coronaviruses: An Updated Overview of Their Replication and Pathogenesis.Methods in molecular biology (Clifton, N.J.) · 2020
    Review
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Alimuddin ZumlaDivision of Infection and Immunity, Center for Clinical Microbiology, University College London, London, UK; NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK.
Ziad A MemishInfectious Diseases Division, Department of Medicine and Department of Research, Prince Mohamed Bin Abdulaziz Hospital, Riyadh, Saudi Arabia; Ministry of Health and College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
David S HuiDivision of Respiratory Medicine and Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Special Administrative Region, China.
Stanley PerlmanDepartment of Microbiology and Immunology and Department of Pediatrics, University of Iowa, Iowa City, IA 52242, USA. Electronic address: stanley-perlman@uiowa.edu.

Funding

SARS-CoV Proteins in Heterologous Viral InfectionP01AI060699 · NIAID · UNIVERSITY OF IOWA · PI PERLMAN, STANLEY · 2004 to 2021
$21.5M
Role of eicosanoids in pathogenic human CoV infectionsR01AI129269 · NIAID · UNIVERSITY OF IOWA · PI Stanley Perlman · 2016 to 2026
$4.7M
NIAID NIH HHS P01 AI060699NIAID NIH HHS R01 AI129269
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Coronavirus InfectionsVaccines, DNAViral VaccinesHumansMiddle East Respiratory Syndrome CoronavirusVaccines, DNAViral Vaccines

Identifiers

PMID31559955
PMCPMC7129953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.